Literature DB >> 36064752

Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant.

Chikara Ogimi1,2,3,4, Elizabeth M Krantz5, Jonathan L Golob5, Catherine Liu6,5, Alpana Waghmare7,6,5, Ashley Akramoff7, Anthony Mallory7, Wendy M Leisenring8, Keith R Jerome5,9, Victor A Chow8,10, Steven A Pergam5,8,11, David N Fredricks5,8,11, Janet A Englund7,6, Michael Boeckh12,13,14.   

Abstract

We examined associations between specific antibiotic exposures and progression to lower respiratory tract disease (LRTD) following individual respiratory viral infections (RVIs) after hematopoietic cell transplantation (HCT). We analyzed allogeneic HCT recipients of all ages with their first RVI during the first 100 days post-HCT. For the 21 days before RVI onset, we recorded any receipt of specific groups of antibiotics, and the cumulative sum of the number of antibiotics received for each day (antibiotic-days). We used Cox proportional hazards models to assess the relationship between antibiotic exposure and progression to LRTD. Among 469 patients with RVI, 124 progressed to LRTD. Compared to no antibiotics, use of antibiotics with broad anaerobic activity in the prior 21 days was associated with progression to LRTD after adjusting for age, virus type, hypoalbuminemia, neutropenia, steroid use, and monocytopenia (HR 2.2, 95% CI 1.1-4.1). Greater use of those antibiotics (≥7 antibiotic days) was also associated with LRTD in adjusted models (HR 2.2, 95% CI 1.1-4.3). Results were similar after adjusting for lymphopenia instead of monocytopenia. Antibiotic use is associated with LRTD after RVI across different viruses in HCT recipients. Prospective studies using anaerobe-sparing antibiotics should be explored to assess impact on LRTD in patients undergoing HCT.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 36064752     DOI: 10.1038/s41409-022-01790-8

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.174


  38 in total

1.  The microbial metabolite desaminotyrosine protects from influenza through type I interferon.

Authors:  Ashley L Steed; George P Christophi; Gerard E Kaiko; Lulu Sun; Victoria M Goodwin; Umang Jain; Ekaterina Esaulova; Maxim N Artyomov; David J Morales; Michael J Holtzman; Adrianus C M Boon; Deborah J Lenschow; Thaddeus S Stappenbeck
Journal:  Science       Date:  2017-08-04       Impact factor: 47.728

2.  Microbiota regulates immune defense against respiratory tract influenza A virus infection.

Authors:  Takeshi Ichinohe; Iris K Pang; Yosuke Kumamoto; David R Peaper; John H Ho; Thomas S Murray; Akiko Iwasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-14       Impact factor: 11.205

3.  Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.

Authors:  Anne Bergeron; Sylvie Chevret; Angela Granata; Patrice Chevallier; Laure Vincent; Anne Huynh; Reza Tabrizi; Hélène Labussiere-Wallet; Marc Bernard; Sylvain Chantepie; Jacques-Olivier Bay; Anne Thiebaut-Bertrand; Sylvain Thepot; Nathalie Contentin; Luc-Matthieu Fornecker; Natacha Maillard; Karine Risso; Ana Berceanu; Didier Blaise; Regis Peffault de La Tour; Jason W Chien; Valérie Coiteux; Gérard Socié
Journal:  JAMA       Date:  2017-08-08       Impact factor: 56.272

4.  Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation.

Authors:  N Khanna; I Steffen; J-D Studt; A Schreiber; T Lehmann; M Weisser; U Flückiger; A Gratwohl; J Halter; H H Hirsch
Journal:  Transpl Infect Dis       Date:  2009-01-20       Impact factor: 2.228

Review 5.  Severe viral respiratory infections: are bugs bugging?

Authors:  M Vissers; R de Groot; G Ferwerda
Journal:  Mucosal Immunol       Date:  2013-11-13       Impact factor: 7.313

6.  Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature.

Authors:  Nina Khanna; Andreas F Widmer; Michael Decker; Ingrid Steffen; Jörg Halter; Dominik Heim; Maja Weisser; Alois Gratwohl; Ursula Fluckiger; Hans H Hirsch
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

7.  Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection.

Authors:  Konrad C Bradley; Katja Finsterbusch; Daniel Schnepf; Stefania Crotta; Miriam Llorian; Sophia Davidson; Serge Y Fuchs; Peter Staeheli; Andreas Wack
Journal:  Cell Rep       Date:  2019-07-02       Impact factor: 9.423

8.  Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.

Authors:  Yasmin Spahr; Sarah Tschudin-Sutter; Veronika Baettig; Francesca Compagno; Michael Tamm; Jörg Halter; Sabine Gerull; Jakob Passweg; Hans H Hirsch; Nina Khanna
Journal:  Open Forum Infect Dis       Date:  2018-04-12       Impact factor: 3.835

9.  Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies.

Authors:  Erik Vakil; Ajay Sheshadri; Saadia A Faiz; Dimpy P Shah; Yayuan Zhu; Liang Li; Joumana Kmeid; Jacques Azzi; Amulya Balagani; Lara Bashoura; Ella Ariza-Heredia; Roy F Chemaly
Journal:  Transpl Infect Dis       Date:  2018-09-21       Impact factor: 2.228

10.  Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections.

Authors:  José Luis Piñana; María Dolores Gómez; Ariadna Pérez; Silvia Madrid; Aitana Balaguer-Roselló; Estela Giménez; Juan Montoro; Eva María González; Víctor Vinuesa; Paula Moles; Juan Carlos Hernández-Boluda; Miguel Salavert; Marisa Calabuig; Guillermo Sanz; Carlos Solano; Jaime Sanz; David Navarro
Journal:  Transpl Infect Dis       Date:  2018-06-22       Impact factor: 2.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.